Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gynecologic Cancer: early-phase trial registry
27 of 56 indexed Gynecologic Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #252 of 28,707 conditions by registered trial count.
56 US clinical trials · 27 currently recruiting · #252 of 28,707 conditions by registered trial count
Gynecologic Cancer: 56 US clinical trials tracked, 27 recruiting.
Gynecologic Cancer is the subject of 56 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 6 of these trials.
Enrollment posture brief
Registry condition gynecologic-cancer
OPEN 27 | RECR 48% | LATE 2 | EARLY 16 | RANK #252 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Advanced Solid Tumors (48% recruiting · 145 trials)
Gynecologic Cancer lists 27 open slots (48% of 56 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gynecologic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gynecologic Cancer is recruiting above its size-band peers.
27 of 56 indexed trials (48.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gynecologic Cancer trials is spread across many organizations.
Dana-Farber Cancer Institute accounts for 6 of 56 trials (10.7%). 37 distinct sponsors appear on at least one study for this condition label.
-
Most Gynecologic Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 56 trials that report a genuine target (sentinel values excluded). 34 of those (60.7%) plan for fewer than 100 participants.
-
Gynecologic Cancer research is mostly interventional.
46 interventional and 10 observational studies make up this index (82.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
56 total, page 1 of 2
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Avera McKennan Hospital & University Health Center
NCT05142033
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
UMC Utrecht
NCT04075305
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
The New York Proton Center
NCT05313191
BOLSTER: Learning New Skills to Thrive
Dana-Farber Cancer Institute
NCT06936878
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
University of California, San Francisco
NCT06089083
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT05053230
Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2
Duke University
NCT06139458
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
Weill Medical College of Cornell University
NCT05562778
Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT
University of California, San Francisco
NCT06633224
Mindfulness in Endometrial and Cervical Cancer
St. Louis University
NCT04512144
The Florida ASCENT Study
University of Florida
NCT07042243
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
University of Utah
NCT07151391
Improve Cancer-related Cognitive Impairment
University of Alabama at Birmingham
NCT05864274
Exercise and Movement to Enhance Resiliency in Cancer Patients
University of California, San Francisco
NCT06809933
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
NCT06580002
Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients
University of Utah
NCT07173101
Molecular and Cellular Profiling of Uterine Lavage Collected During Gynecologic Surgery
Stanford University
NCT07044505
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
NCT05559879
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
University of Utah
NCT07166042
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
NCT06342986
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
NCT06677190
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
Viome
NCT04957511
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
NCT07447050
Novel Imaging Technique to Assess Gynecologic Cancer
Memorial Sloan Kettering Cancer Center
NCT04893434
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
University of Utah
NCT07120100
Activity Coaching During Pelvic Radiation Therapy
Inova Health Care Services
NCT06746428
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT06673329
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)
Dana-Farber Cancer Institute
NCT05629065
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
M.D. Anderson Cancer Center
NCT05677048
Patient Related Outcomes for Gynecologic Radiation Oncology
UNC Lineberger Comprehensive Cancer Center
NCT04753086
Diet, Hepcidin, and Chemotherapy RDI
George Washington University
NCT06483997
Improving Sleep in Gynecologic Cancer Survivors
University of Arizona
NCT05044975
The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy
Augusta University
NCT05980169
Psychosexual Educational Partners Program (PEPP)
The University of Tennessee, Knoxville
NCT06253182
Clinical Investigation of the da Vinci Surgical System
Intuitive Surgical
NCT05682742
Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer
Dana-Farber Cancer Institute
NCT03277469
Acupuncture Pilot Study for Cancer-related Cognitive Function
Memorial Sloan Kettering Cancer Center
NCT04007770
An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer
Memorial Sloan Kettering Cancer Center
NCT03794635
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
NCT05704985
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
Elizabeth K. Lee MD
NCT05296512
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
Rutgers, The State University of New Jersey
NCT05220033
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Cancer Institute (NCI)
NCT05185947
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
AgonOx
NCT05902520
Improving Women's Function After Pelvic Radiation
Duke University
NCT04544735
A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer
Dana-Farber Cancer Institute
NCT03970083
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study
Stanford University
NCT03245788
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
Alliance for Clinical Trials in Oncology
NCT01376349
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
University of Colorado, Denver
NCT02366871
Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients
M.D. Anderson Cancer Center
NCT01031602
Patient-Centered Intervention to Reduce Cancer Patients' Financial Toxicity
Washington University School of Medicine
NCT04314284
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 10 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Gynecologic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gynecologic Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gynecologic Cancer page
56 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Gynecologic Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Gynecologic Cancer trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gynecologic Cancer condition card totals 56 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.